Proactive Investors - Run By Investors For Investors

OptiBiotix Health gets licence to manufacture weight management product Slimbiome in India

Stephen O'Hara, OptiBiotix’s CEO commented: "Achieving FSSAI approval so quickly is a significant achievement and is an important step in completing the supply chain"
Slim woman
OptiBiotix revealed at the start of January this year that it had inked an agreement with Zeon in return for a 50% share of the profits

OptiBiotix Health PLC (LON:OPTI) said it has received a licence from the Food Standards and Safety Authority India (FSSAI) for its award-winning weight management product, SlimBiome to be manufactured in India.

The AIM-listed life sciences firm said approval was gained by OptiBiotix's manufacturing partner, Zeon Life Sciences, for both SlimBiome and SlimBiome containing products.

READ: OptiBiotix jumps as it inks supply and profit sharing agreement for SlimBiome in India

It pointed out that FSSAI licence approval involves both ingredient and quality verification to ensure the product and manufacturing process is of a high standard and is an essential regulatory requirement to manufacture and distribute food products in India.

The licence approval allows Zeon to fulfil orders arising from OptiBiotix's recent visit to India for SlimBiome and SlimBiome containing products in its own manufacturing site. 

The group said: ”This is a strategic step by OptiBiotix to add manufacturing in Asia to the supply chain and extend the market opportunity for its patented award-winning weight management product into the fast-growing Indian market with an established partner.”

It noted that Zeon includes major Indian and international healthcare companies such as Danone, GNC, Decathlon, Sun Pharma and Herbalife amongst its customers and was awarded Nutraceutical Manufacturing Company of the Year in 2017 by The Associated Chambers of Commerce and Industry of India.

Stephen O'Hara, OptiBiotix’s CEO commented: "Achieving FSSAI approval so quickly is a significant achievement and is an important step in completing the supply chain to meet the needs of existing and new corporate partners in India and Southern Asia.

“This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, and white label and own label branded consumer and pharmaceutical products across multiple channels with industry partners from around the world."

OptiBiotix revealed at the start of January this year that it had inked an agreement with Zeon, granting the firm an exclusive licence to manufacture and supply SlimBiome in India in return for a 50% share of the profits.

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use